Generic drugs currently account for 70 % of all prescriptions handed out through National Health Insurance but only 25 % of all pharmaceutical billings, while the other 75 % goes to international pharmaceuticals giants that make expensive patent-protected or brand-name pharmaceuticals (the latter of which, even after patents expire, continue to command a higher price than generic drugs due to trust in the brand).
目前國產學名藥總計供應了 7 成的健保用藥，但卻只得到 25％的藥品給付；其餘高達 75％，都進了擁有高價專利藥及原廠藥（專利雖已過期，但仍由原廠生產，其藥效被認為優於一般藥廠仿製的學名藥）的國際大廠口袋。